Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) will likely be announcing its Q4 2024 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter.
Avalo Therapeutics Stock Down 6.7 %
AVTX stock opened at $4.06 on Friday. Avalo Therapeutics has a 1 year low of $4.06 and a 1 year high of $16.00. The company has a fifty day simple moving average of $6.14 and a 200 day simple moving average of $8.14.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on AVTX. HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Stifel Nicolaus assumed coverage on Avalo Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $36.00 price target on the stock. Jefferies Financial Group started coverage on shares of Avalo Therapeutics in a research note on Tuesday, March 25th. They issued a “buy” rating and a $23.00 price objective for the company. Piper Sandler initiated coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and set a $18.00 target price on shares of Avalo Therapeutics in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.00.
About Avalo Therapeutics
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Further Reading
- Five stocks we like better than Avalo Therapeutics
- What is diluted earnings per share (Diluted EPS)?
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Here’s The Reason Goldman Sachs Is Bullish On MercadoLibre Stock
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
